Table 2 Associations between patient characteristics and adherence score
Factor | Frequency (%) | Median [Q1-Q3] | Mean rank | P value |
|---|---|---|---|---|
Age (years) | 0.277 | |||
< 45 | 32 (30.2) | 5.0 [4.0–6.0] | 46. 67 | |
45–65 | 57 (53.8) | 5.0 [5.0–6.0] | 56.81 | |
> 65 | 17 (16.0) | 5.0 [5.0–6.0] | 55.26 | |
Body mass index | 0.949 | |||
< 18.5 | 2 (1.9) | 5.0 [5.0–6.0] | 64.5 | |
18.5–24.9 | 25 (23.6) | 4.0 [5.0–6.0] | 52.02 | |
25–29.9 | 37 (34.9) | 5.0 [5.0–6.0] | 53.73 | |
≥ 30 | 42 (39.6) | 4.0 [5.0–6.0] | 53.65 | |
Residency | 0.020 | |||
City | 53 (50.0) | 5.0 [5.0–6.0] | 54.88 | |
Village | 45 (42.5) | 5.0 [4.5–6.0] | 56.77 | |
Camp | 8 (7.5) | 4.0 [3.25–4.75] | 26.00 | |
Smoking | 0.360 | |||
No | 89 (84.0) | 5.0 [5.0–6.0] | 59.41 | |
Yes | 17 (16.0) | 5.0 [4.0–6.0] | 52.37 | |
University qualification | 0.619 | |||
No | 71 (67.0) | 5.0 [4.0–6.0] | 52.51 | |
Yes | 35 (33.0) | 5.0 [5.0–6.0] | 55.50 | |
Work | 0.809 | |||
Unemployed | 89 (84.0) | 5.0 [4.5–6.0] | 53.20 | |
Employed | 17 (16.0) | 5.0 [4.5–6.0] | 55.06 | |
Material status | 0.468 | |||
Single | 23 (21.7) | 5.0 [5.0–6.0] | 57.39 | |
Married | 83 (78.3) | 5.0 [4.0–6.0] | 52.42 | |
Family history | 0.399 | |||
No | 46 (43.4) | 5.0 [4.0–6.0] | 50.78 | |
Yes | 60 (56.6) | 5.0 [5.0–6.0] | 55.58 | |
Comorbidities | 0.085 | |||
No | 51 (48.1) | 5.0 [4.0–6.0] | 48.45 | |
Yes | 55 (51.9) | 5.0 [5.0–6.0] | 58.18 | |
Chronic medication | 0.060 | |||
No | 33 (31.1) | 5.0 [4.0–6.0] | 45.61 | |
Yes | 73 (68.9) | 5.0 [5.0–6.0] | 57.07 | |
Number of clinic visits per year | 0.264 | |||
< 12 | 29 (27.4) | 5.0 [4.0–6.0] | 48.36 | |
≥ 12 | 77 (72.6) | 5.0 [5.0–6.0] | 55.44 | |
Hospitalized in the last year | 0.972 | |||
No | 69 (65.1) | 5.0 [4.0–6.0] | 53.43 | |
Yes | 37 (34.9) | 5.0 [5.0–6.0] | 53.64 | |
Breast surgery | 0.986 | |||
No | 20 (18.9) | 5.0 [4.25–6.0] | 53.60 | |
Yes | 86 (81.1) | 5.0 [4.75–6.0] | 53.48 | |
Radiotherapy | 0.894 | |||
No | 37 (34.9) | 5.0 [4.5–6.0] | 52.99 | |
Yes | 69 (65.1) | 5.0 [4.5–6.0] | 53.78 | |
Chemotherapy | 0.246 | |||
No | 21 (18.9) | 6.0 [5.0–6.0] | 60.10 | |
Yes | 85 (80.2) | 5.0 [4.0–6.0] | 51.87 | |
Biological therapy | 0.915 | |||
No | 86 (81.1) | 5.0 [4.0–6.0] | 53.35 | |
Yes | 20 (19.8) | 5.0 [5.0–6.0] | 54.13 | |
Targeted therapy | 0.676 | |||
No | 86 (81.1) | 5.0 [5.0–6.0] | 54.07 | |
Yes | 20 (18.9) | 5.0 [4.0–6.0] | 51.05 | |
Current hormonal therapy | 0.825 | |||
Tamoxifen | 33 (31.1) | 5.0 [4.0–6.0] | 50.08 | |
Exemestane | 18 (17.0) | 5.0 [4.0–6.0] | 54.86 | |
Letrozole | 41 (38.7) | 5.0 [5.0–6.0] | 56.22 | |
Anastrozole | 14 (13.2) | 5.0 [4.0–6.0] | 51.86 | |
Hormonal drug switching | 0.064 | |||
No | 76 (71.7) | 5.0 [4.5–6.0] | 56.78 | |
Yes | 30 (28.3) | 5.0 [4.5–6.0] | 45.18 | |
Duration of starting current hormonal therapy | 0.303 | |||
< 1 year | 36 (34.0) | 5.0 [4.0–6.0] | 49.44 | |
≥ 1 year | 70 (66.0) | 5.0 [5.0–6.0] | 55.59 | |
HER2 status | 0.690 | |||
Negative | 82 (77.4) | 5.0 [4.75–6.0] | 54.11 | |
Positive | 24 (22.6) | 5.0 [4.25–6.0] | 51.42 | |
Disease recurrence | 0.861 | |||
No | 95 (89.6) | 5.0 [5.0–6.0] | 53.33 | |
Yes | 11 (10.4) | 5.0 [4.0–6.0] | 54.95 | |
Menopausal status | 0.478 | |||
Premenopause | 56 (52.8) | 5.0 [4.0–6.0] | 51.61 | |
Postmenopause | 50 (47.2) | 5.0 [5.0–6.0] | 55.62 |